A doctor in Japan has been arrested in connection with allegations of bribery relating to Nippon Glaxo, the UK drug company Glaxo's Japanese unit. It is alleged that the doctor received around 1 million yen ($10,163) from the company for arranging clinical tests for Glaxo's antihypertensive agent Lacipil (lacidipine).
Nippon Japan is denying the allegations, but last week requested the Japanese Ministry of Health and Welfare to withdraw its application for approval of the product (see page 22).
The arrest of the doctor, who works at the National Harashino Hospital, follows the arrest earlier this month of an assistant at the National Kagawa Hospital. The latter is accused of administering the test drug to patients without being granted their permission, according to local reports. In the UK, Glaxo was not making further comment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze